APUS Valuation
Apimeds Pharmaceuticals US Inc
$
1.940
- Overview
- Forecast
- Valuation
- Earnings
APUS Relative Valuation
APUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APUS is overvalued; if below, it's undervalued.
Historical Valuation
Apimeds Pharmaceuticals US Inc (APUS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Apimeds Pharmaceuticals US Inc (APUS) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.94
Fair
0.00
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Apimeds Pharmaceuticals US Inc. (APUS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Apimeds Pharmaceuticals US Inc. (APUS) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Apimeds Pharmaceuticals US Inc. (APUS) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Apimeds Pharmaceuticals US Inc. (APUS) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Apimeds Pharmaceuticals US Inc. (APUS) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Apimeds Pharmaceuticals US Inc (APUS) has a current Price-to-Book (P/B) ratio of 2.45. Compared to its 3-year average P/B ratio of -2.85 , the current P/B ratio is approximately -186.25% higher. Relative to its 5-year average P/B ratio of -2.85, the current P/B ratio is about -186.25% higher. Apimeds Pharmaceuticals US Inc (APUS) has a Forward Free Cash Flow (FCF) yield of approximately -16.26%. Compared to its 3-year average FCF yield of -9.78%, the current FCF yield is approximately 66.34% lower. Relative to its 5-year average FCF yield of -9.78% , the current FCF yield is about 66.34% lower.
2.45
P/B
Median3y
-2.85
Median5y
-2.85
-16.26
FCF Yield
Median3y
-9.78
Median5y
-9.78
Competitors Valuation Multiple
The average P/S ratio for APUS's competitors is 48.32, providing a benchmark for relative valuation. Apimeds Pharmaceuticals US Inc Corp (APUS) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APUS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of APUS in the past 1 year is driven by Unknown.
People Also Watch
META
Meta Platforms Inc
737.050
USD
+0.26%
AAPL
Apple Inc
238.470
USD
+3.81%
TSLA
Tesla Inc
334.090
USD
+1.44%
MSFT
Microsoft Corp
505.350
USD
+0.05%
ORCL
Oracle Corp
223.450
USD
-0.82%
XOM
Exxon Mobil Corp
111.910
USD
-2.42%
WMT
Walmart Inc
99.440
USD
+1.62%
NVDA
NVIDIA Corp
170.620
USD
-0.09%
AMZN
Amazon.com Inc
225.990
USD
+0.29%
AVGO
Broadcom Inc
302.390
USD
+1.39%
FAQ
Is Apimeds Pharmaceuticals US Inc (APUS) currently overvalued or undervalued?
Apimeds Pharmaceuticals US Inc (APUS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Apimeds Pharmaceuticals US Inc (APUS) is between to according to relative valuation methord.
What is Apimeds Pharmaceuticals US Inc (APUS) fair value?
How does APUS's valuation metrics compare to the industry average?
What is the current P/B ratio for Apimeds Pharmaceuticals US Inc (APUS) as of Sep 04 2025?
What is the current FCF Yield for Apimeds Pharmaceuticals US Inc (APUS) as of Sep 04 2025?
What is the current Forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS) as of Sep 04 2025?